Univariate and multivariate analysis of PFS outcome in the MajesTEC-1 study cohort. (A) Univariate analysis of the effect of the BMPC, cytogenetic risk, extramedullary disease, and sBCMA 400 ng/mL cutoff on the PFS outcome. (B) Univariate analysis of sBCMA levels (400 ng or median cutoff) in the subgroup of patients with EMD. (C) Multivariate analysis that included EMD and sBCMA to determine the effect on PFS patient outcome.